Johnson & Johnson
JNJ
256.48
-1.97
-0.76%
Johnson & Johnson
US · JNJ
#25 by market cap
Listed 1970
256.48
-1.97
-0.76%
Live - 5344 symbols - heartbeat 95s ago
· 2026-10-08 18:49
Pre-market
257.48
-0.38%
After-hours
256.77
+0.11%
Overnight
257.75
-0.27%
- Market cap
- 618.09B
- P/E (TTM)i
- 29.75
- P/Bi
- 7.27
- EPSi
- 11.03
- Div yieldi
- 2.04%
- 52W posi
- 76%
Reader sentiment
Are you bullish or bearish on JNJ?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 25 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.1 percentage points.
Institutional ownership
- Held by institutions
- 76.55% -0.10pp
- Institutions
- 5,317 -25
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund62.69%
Public Company4.79%
Private Company3.43%
Government Pension Fund2.04%
Sovereign Wealth Fund1.41%
Hedge Fund0.95%
Family Office/Trust0.50%
Insurance Company0.35%
Government0.12%
VC/PE Fund0.14%
Other23.71%
Top holders as of 2026-06-30
BlackRock
8.80% · 212.10M sh
Vanguard Capital Management, LLC
7.09% · 170.74M sh
State Street Global Advisors
5.55% · 133.78M sh
Vanguard Portfolio Management, LLC
2.67% · 64.37M sh
Geode Capital Management, LLC
2.45% · 59.09M sh
Other
73.44%
J.P. Morgan Asset Management, Inc.
1.86% · 44.73M sh
Norges Bank Investment Management
1.32% · 31.83M sh
State Farm Mutual Automobile Insurance Company
1.31% · 31.59M sh
UBS Asset Management
1.22% · 29.45M sh
Northern Trust Global Investments
1.19% · 28.79M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 27 buys · 20 sells
| Name | Role | Stake |
|---|---|---|
| Joaquin Duato | Chairperson & CEO | 0.01% |
| Jennifer Taubert | Executive VP & Worldwide Chairman of Pharmaceuticals | 0.01% |
| Kathryn Wengel | Executive VP and Chief Technical Operations & Risk Officer | 0.00% |
| Joseph Wolk | Chief Financial Officer | 0.00% |
| Timothy Schmid | Executive VP & Worldwide Chairman of MedTech | 0.00% |
| James Swanson | Executive Vice President | 0.00% |
| John Reed | Executive Vice President of Pharmaceuticals, R&D | 0.00% |
| Robert Decker | Controller & Chief Accounting Officer | 0.00% |
| Vanessa Broadhurst | Executive Vice President of Global Corporate Affairs | 0.00% |
| Kristen Mulholland | Head of Human Resources of Global Total Rewards | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-07 | Marillyn Hewson | Independent Director | Other Derivative Acquisition | +180 | -- |
| 2026-09-07 | Eugene Woods | Director | Other Derivative Acquisition | +135 | -- |
| 2026-09-07 | Daniel Pinto | Director | Other Derivative Acquisition | +113 | -- |
| 2026-09-01 | Timothy Schmid | Executive VP & Worldwide Chairman of MedTech | Derivative Exercise and Sale | -33,597 | $131.94–274.74 |
| 2026-08-31 | Tom Cavanaugh | Company Group Chairman for North America Innovative Medicine | Initial Statement of Beneficial | 0 | -- |
| 2026-08-16 | Jennifer Taubert | Executive VP & Worldwide Chairman of Pharmaceuticals | Derivative Exercise and Sale | -15,000 | $115.67–263.36 |
| 2026-08-12 | Joaquin Duato | Chairperson & CEO | Derivative Exercise and Sale | -123,291 | $115.67–262.00 |
| 2026-08-05 | Elizabeth Forminard | Executive Vice President | Open Market Disposition | -6,574 | $255.93 |
| 2026-08-05 | Elizabeth Forminard | Executive Vice President | Derivative Exercise and Sale | -9,344 | $131.94–257.76 |
| 2026-08-04 | Joaquin Duato | Chairperson & CEO | Open Market Disposition | -48,480 | $258.06–258.74 |
| 2026-07-19 | Vanessa Broadhurst | Executive Vice President of Global Corporate Affairs | Derivative Exercise and Sale | -23,054 | $129.51–251.27 |
| 2026-06-10 | Kathryn Wengel | Executive VP and Chief Technical Operations & Risk Officer | Derivative Exercise and Sale | -10,000 | $115.67–241.15 |
| 2026-06-08 | Marillyn Hewson | Independent Director | Other Derivative Acquisition | +214 | -- |
| 2026-06-08 | Eugene Woods | Director | Other Derivative Acquisition | +161 | -- |
| 2026-06-08 | Daniel Pinto | Director | Other Derivative Acquisition | +134 | -- |
| 2026-04-30 | John Reed | Executive Vice President of Pharmaceuticals, R&D | Derivative Exercise and Sale | -11,002 | $229.85 |
| 2026-04-30 | John Reed | Executive Vice President of Pharmaceuticals, R&D | Derivative Exercise and Retained | +14,253 | -- |
| 2026-04-22 | John Morikis | Director | Other Derivative Acquisition | +1,540 | -- |
| 2026-04-22 | Hubert Joly | Independent Director | Other Derivative Acquisition | +975 | -- |
| 2026-04-22 | Marillyn Hewson | Independent Director | Other Derivative Acquisition | +975 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 18:49:01 · For reference only, not investment advice and not tailored to your situation.